About Purohit Navigation

This author has not yet filled in any details.
So far Purohit Navigation has created 11 blog entries.

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2024-01-01T17:33:51-05:00January 3, 2024|Press Release|0 Comments
Read More

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2024-01-01T17:34:44-05:00January 2, 2024|Press Release|0 Comments
Read More

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2023-12-05T09:51:39-05:00December 5, 2023|Press Release|0 Comments
Read More

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...

By |2023-09-04T22:05:36-04:00September 5, 2023|Press Release|0 Comments
Read More

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...

By |2023-05-22T22:49:30-04:00May 23, 2023|Press Release|0 Comments
Read More

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...

By |2023-05-05T09:50:48-04:00April 6, 2023|Press Release|0 Comments
Read More

Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting

By |2022-12-05T18:43:44-05:00November 3, 2022|Press Release|0 Comments
Read More

Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) [...]

By |2022-12-05T18:44:13-05:00February 16, 2022|Press Release|0 Comments
Read More

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies

Drug discovery approach uncovers novel biology for treatments that can [...]

By |2022-12-05T18:39:45-05:00February 16, 2022|Press Release|0 Comments
Read More

© 2023 STAR Therapeutics Inc.

THANK YOU

We look forward to connecting with you